There are no files associated with this item.
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.citation.endPage | 680 | - |
dc.citation.number | 5 | - |
dc.citation.startPage | 672 | - |
dc.citation.title | BREAST CANCER | - |
dc.citation.volume | 26 | - |
dc.contributor.author | Lee, Anbok | - |
dc.contributor.author | Jo, Sunmi | - |
dc.contributor.author | Lee, Changhu | - |
dc.contributor.author | Shin, Hyun-Hee | - |
dc.contributor.author | Kim, Tae Hyun | - |
dc.contributor.author | Ahn, Ki Jung | - |
dc.contributor.author | Park, Sung-Kwang | - |
dc.contributor.author | Cho, Heunglae | - |
dc.contributor.author | Yoon, Hye-Kyoung | - |
dc.contributor.author | Kim, Woo Gyeong | - |
dc.contributor.author | Park, Jiyoung | - |
dc.contributor.author | Choi, Yunseon | - |
dc.date.accessioned | 2023-12-21T18:47:12Z | - |
dc.date.available | 2023-12-21T18:47:12Z | - |
dc.date.created | 2019-04-01 | - |
dc.date.issued | 2019-09 | - |
dc.description.abstract | Purpose: Recent studies revealed that metabolic stress influences the outcomes of breast cancer treatment. We sought to evaluate the prognostic effect of type 2 diabetes and find the molecular mechanism of relapses in postoperative HER-2+ breast cancer patients treated with HER-2 targeted therapy. Materials and methods: We evaluated 190 HER-2+ breast cancer patients (pT1-4N0-2M0) who were treated with surgical resection and trastuzumab (HER-2 targeted therapy) between 2006 and 2015. Survival outcomes and failure patterns were compared between such patients with (n = 12) and without (n = 178) type 2 diabetes. Results: The median follow-up period was 42.4 months (range 12.0–124.7 months). Twenty-one patients (11.1%) showed relapse (including nine patients with locoregional failure), and three patients (1.6%) died as a result of cancer relapse. One-third of the patients with diabetes experienced relapse (4/12, 33.3%). The 3-year disease-free survival (DFS) and overall survival (OS) rates were 90.7% and 98.6%, respectively. Diabetic patients showed shorter DFS compared with non-diabetic patients (p = 0.006, 74.1% vs. 91.9%). OS was also shorter in diabetic patients compared with non-diabetic patients (p = 0.017, 91.7% vs. 99.1%). Of our interest, the levels of HER-3 and its ligand neuregulin-1 were significantly increased in the tumor specimen in HER-2+ breast cancer patients suffering with type 2 diabetes than that in the euglycemic control group. Conclusions: Type 2 diabetes was associated with detrimental effects on survival in postoperative HER-2+ breast cancer patients who were treated with trastuzumab. The poor prognostic effect of diabetes in HER-2+ breast cancer patients could be associated with the high levels of HER-3 and neuregulin 1, thus it should be considered and evaluated more. |
- |
dc.identifier.bibliographicCitation | BREAST CANCER, v.26, no.5, pp.672 - 680 | - |
dc.identifier.doi | 10.1007/s12282-019-00967-2 | - |
dc.identifier.issn | 1340-6868 | - |
dc.identifier.scopusid | 2-s2.0-85064251720 | - |
dc.identifier.uri | https://scholarworks.unist.ac.kr/handle/201301/26433 | - |
dc.identifier.url | https://link.springer.com/article/10.1007%2Fs12282-019-00967-2 | - |
dc.identifier.wosid | 000481427100017 | - |
dc.language | 영어 | - |
dc.publisher | Springer Nature | - |
dc.title | Diabetes as a prognostic factor in HER-2 positive breast cancer patients treated with targeted therapy | - |
dc.type | Article | - |
dc.description.isOpenAccess | FALSE | - |
dc.relation.journalWebOfScienceCategory | Oncology; Obstetrics & Gynecology | - |
dc.relation.journalResearchArea | Oncology; Obstetrics & Gynecology | - |
dc.type.docType | Article | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.subject.keywordAuthor | HER-2 positive breast cancer | - |
dc.subject.keywordAuthor | Trastuzumab | - |
dc.subject.keywordAuthor | Diabetes | - |
dc.subject.keywordAuthor | Survival | - |
dc.subject.keywordAuthor | Prognostic factor | - |
dc.subject.keywordPlus | LARGE COHORT | - |
dc.subject.keywordPlus | SURVIVAL | - |
dc.subject.keywordPlus | TRASTUZUMAB | - |
dc.subject.keywordPlus | RISK | - |
dc.subject.keywordPlus | RESISTANCE | - |
dc.subject.keywordPlus | RECEPTOR | - |
dc.subject.keywordPlus | OVEREXPRESSION | - |
dc.subject.keywordPlus | ASSOCIATIONS | - |
dc.subject.keywordPlus | INCREASES | - |
dc.subject.keywordPlus | CONSENSUS | - |
Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.
Tel : 052-217-1404 / Email : scholarworks@unist.ac.kr
Copyright (c) 2023 by UNIST LIBRARY. All rights reserved.
ScholarWorks@UNIST was established as an OAK Project for the National Library of Korea.